Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma × Tolbutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Synovitis, Pigmented Villonodular 1 Lymphoma 1

Interventions

Rituximab 57 Cyclophosphamide 34 fludarabine 20 Bendamustine Hydrochloride 20 pembrolizumab 18 Brentuximab Vedotin 18 Gemcitabine 17 Prednisone 16 Doxorubicin 16 ibrutinib 15 obinutuzumab 14 Vincristine 13 Nivolumab 9 Lenalidomide 9 parsaclisib 7 atezolizumab 7 Rifampin 7 Dexamethasone 7 Azacitidine 7 spartalizumab 6 loncastuximab tesirine 6 duvelisib 6 Vorinostat 6 MLN 8237 6 venetoclax 5 Etoposide 5 zanubrutinib 4 rasburicase 4 ixazomib 4 idelalisib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01185548 2018-10-19

JZAR

Eli Lilly and Company

Phase 1 Terminated

4 enrolled 8 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡